Isobel joined Abingworth’s London office in November 2026 and works with the transatlantic team to source new investment opportunities and support existing portfolio companies.
Prior to joining Abingworth, Isobel was a strategy consultant in L.E.K.’s Life Sciences practice, advising pharmaceutical clients and investors on growth strategy and commercial due diligence. A secondment provided private equity-focused origination experience. Following her MBA, Isobel also supported strategy development at AdvanCell, an Abingworth portfolio company.
Isobel holds an MBA from INSEAD and a degree in Biological Natural Sciences from the University of Cambridge.
